DK3024489T3 - Salte af 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-on-derivater med både muscarinreceptorantagonist- og beta-2-adrenerg-receptoragonistaktiviteter - Google Patents

Salte af 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-on-derivater med både muscarinreceptorantagonist- og beta-2-adrenerg-receptoragonistaktiviteter Download PDF

Info

Publication number
DK3024489T3
DK3024489T3 DK14747554.5T DK14747554T DK3024489T3 DK 3024489 T3 DK3024489 T3 DK 3024489T3 DK 14747554 T DK14747554 T DK 14747554T DK 3024489 T3 DK3024489 T3 DK 3024489T3
Authority
DK
Denmark
Prior art keywords
hydroxyquinoline
hydroxyethyl
beta
derivatives
salts
Prior art date
Application number
DK14747554.5T
Other languages
Danish (da)
English (en)
Inventor
Carrera Francesc Carrera
Jane Montserrat Julia
Lorenzo Francesca Pajuelo
Andres Juan Antonio Perez
Quiñones Maria Prat
Duran Carlos Puig
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3024489(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Application granted granted Critical
Publication of DK3024489T3 publication Critical patent/DK3024489T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK14747554.5T 2013-07-25 2014-07-24 Salte af 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-on-derivater med både muscarinreceptorantagonist- og beta-2-adrenerg-receptoragonistaktiviteter DK3024489T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382304 2013-07-25
PCT/EP2014/065965 WO2015011244A1 (en) 2013-07-25 2014-07-24 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES

Publications (1)

Publication Number Publication Date
DK3024489T3 true DK3024489T3 (da) 2020-05-04

Family

ID=48917474

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14747554.5T DK3024489T3 (da) 2013-07-25 2014-07-24 Salte af 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-on-derivater med både muscarinreceptorantagonist- og beta-2-adrenerg-receptoragonistaktiviteter

Country Status (36)

Country Link
US (1) US9579316B2 (enExample)
EP (1) EP3024489B1 (enExample)
JP (1) JP6374962B2 (enExample)
KR (1) KR102338155B1 (enExample)
CN (2) CN112321579A (enExample)
AR (1) AR097079A1 (enExample)
AU (1) AU2014295028B2 (enExample)
BR (1) BR112016001295B1 (enExample)
CA (1) CA2917596C (enExample)
CL (1) CL2016000187A1 (enExample)
CR (1) CR20160043A (enExample)
CY (1) CY1122920T1 (enExample)
DK (1) DK3024489T3 (enExample)
DO (1) DOP2016000011A (enExample)
EA (1) EA035436B1 (enExample)
ES (1) ES2788627T3 (enExample)
HR (1) HRP20200670T1 (enExample)
HU (1) HUE049441T2 (enExample)
IL (1) IL243173B (enExample)
LT (1) LT3024489T (enExample)
MX (1) MX360837B (enExample)
MY (1) MY184681A (enExample)
NI (1) NI201600012A (enExample)
NZ (1) NZ715128A (enExample)
PE (1) PE20160173A1 (enExample)
PH (1) PH12016500125A1 (enExample)
PL (1) PL3024489T3 (enExample)
PT (1) PT3024489T (enExample)
RS (1) RS60185B1 (enExample)
SG (1) SG11201510682YA (enExample)
SI (1) SI3024489T1 (enExample)
SM (1) SMT202000185T1 (enExample)
TW (1) TWI641373B (enExample)
UY (1) UY35678A (enExample)
WO (1) WO2015011244A1 (enExample)
ZA (1) ZA201509203B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク. 乾燥粉末配合および使用方法
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
EP3375781A4 (en) * 2015-07-21 2019-01-09 Sichuan Haisco Pharmaceutical Co., Ltd. BENZORING DERIVATIVE WITH B2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE
CN106554350B (zh) * 2015-09-29 2019-12-20 四川海思科制药有限公司 具有β2激动活性的苯并杂环衍生物及其制法和应用
TW201835041A (zh) * 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
AU2017432640B2 (en) 2017-09-22 2023-11-30 Aspeya US Inc. Dry powder compositions with magnesium stearate
WO2020244452A1 (zh) * 2019-06-06 2020-12-10 中国医药研究开发中心有限公司 具有β 2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
JP2023542161A (ja) * 2020-09-28 2023-10-05 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 縮合三環式誘導体及び薬学上のその使用
CA3246419A1 (en) * 2022-03-25 2025-06-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fused tricyclic derivative crystal or pharmaceutically acceptable salt thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212742B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
EP0147475B1 (en) 1983-09-26 1987-03-18 MAGIS FARMACEUTICI S.p.A. Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
EP0416925A3 (en) 1989-09-07 1991-09-25 Glaxo Group Limited Use of 4-hydroxy-alpha 1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
AU4248597A (en) 1996-09-06 1998-03-26 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
ATE397590T1 (de) 1999-08-20 2008-06-15 Dow Agrosciences Llc Fungizide heterocyclische aromatische amide und deren zusammensetzungen, verfahren zu deren anwendung und herstellung
US6806314B2 (en) 2003-02-03 2004-10-19 Ppg Industries Ohio, Inc. Coating of Hydroxy-functional polymer(s), crosslinker, and 1,3- and 1,4-cyclohexane dimethanols
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
DE602004021921D1 (de) 2003-05-28 2009-08-20 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
US7320990B2 (en) 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
NZ570693A (en) 2006-03-20 2011-02-25 Pfizer Ltd Amine derivatives
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
RS20090137A (sr) 2006-10-04 2010-06-30 Pfizer Limited Sulfonamid derivati kao adrenergijski agonisti i muskarinski antagonisti
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
PE20090907A1 (es) 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
RS52557B (sr) 2008-02-06 2013-04-30 Pulmagen Therapeutics (Synergy) Limited Jedinjenja
CN101544572B (zh) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 一种氨溴索衍生物及其制备方法
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
RU2011101664A (ru) * 2008-06-20 2012-07-27 Астразенека Аб (Se) Фармацевтическая композиция, содержащая 4-гидрокси-2-оксо-2, 3-дигидро-1, 3-бензотиазол-7-ильное соединение, для модулирования активности бета2- адренорецепторов
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
SI3210981T1 (sl) 2009-04-23 2019-05-31 Theravance Respiratory Company, Llc Diamidne spojine, ki imajo muskarinsko receptorsko antagonistično in beta 2 adrenergično receptorsko agonistično aktivnost
MX2011011446A (es) 2009-04-30 2011-11-18 Teijin Pharma Ltd Compuestos de sal de amonio cuaternario.
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
KR101906630B1 (ko) 2011-06-10 2018-10-10 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
RS54365B1 (sr) 2011-06-10 2016-04-28 Chiesi Farmaceutici S.P.A. Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
PL2776038T3 (pl) 2011-11-11 2018-06-29 Gilead Apollo, Llc Inhibitory acc i ich zastosowania
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
TR201807091T4 (tr) 2012-12-06 2018-06-21 Chiesi Farm Spa Radyasyon veya kemoterapi̇ye bağli mukosi̇ti̇n önlenmesi̇ i̇çi̇n bi̇r kombi̇nasyonun kullanimi.
HUE037944T2 (hu) 2012-12-06 2018-09-28 Chiesi Farm Spa Muszkarin receptor antagonista és béta2 adrenerg receptor agonista akitvitással rendelkezõ vegyületek
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TW201440768A (zh) 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物

Also Published As

Publication number Publication date
KR102338155B1 (ko) 2021-12-10
CA2917596C (en) 2021-06-22
EP3024489B1 (en) 2020-02-19
CL2016000187A1 (es) 2016-08-05
UY35678A (es) 2015-02-27
RS60185B1 (sr) 2020-06-30
SG11201510682YA (en) 2016-02-26
ZA201509203B (en) 2017-04-26
PT3024489T (pt) 2020-05-05
MX360837B (es) 2018-11-20
CN112321579A (zh) 2021-02-05
CR20160043A (es) 2016-04-08
AU2014295028B2 (en) 2018-05-31
HK1219043A1 (en) 2017-03-24
PL3024489T3 (pl) 2020-08-10
PE20160173A1 (es) 2016-04-13
HRP20200670T1 (hr) 2020-07-10
TWI641373B (zh) 2018-11-21
ES2788627T3 (es) 2020-10-22
MX2016000397A (es) 2016-04-29
PH12016500125B1 (en) 2016-04-25
DOP2016000011A (es) 2016-06-15
PH12016500125A1 (en) 2016-04-25
HUE049441T2 (hu) 2020-09-28
CY1122920T1 (el) 2021-10-29
EP3024489A1 (en) 2016-06-01
IL243173A0 (en) 2016-02-29
WO2015011244A1 (en) 2015-01-29
EA201600128A1 (ru) 2016-07-29
NZ715128A (en) 2019-03-29
JP6374962B2 (ja) 2018-08-15
CN105492027A (zh) 2016-04-13
BR112016001295A2 (enExample) 2017-07-25
KR20160034310A (ko) 2016-03-29
AR097079A1 (es) 2016-02-17
SMT202000185T1 (it) 2020-05-08
LT3024489T (lt) 2020-03-10
US20160166566A1 (en) 2016-06-16
US9579316B2 (en) 2017-02-28
TW201517907A (zh) 2015-05-16
IL243173B (en) 2019-10-31
JP2016525533A (ja) 2016-08-25
AU2014295028A1 (en) 2016-01-21
BR112016001295B1 (pt) 2022-07-19
NI201600012A (es) 2016-10-10
EA035436B1 (ru) 2020-06-15
MY184681A (en) 2021-04-16
SI3024489T1 (sl) 2020-04-30
CA2917596A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
DK3024489T3 (da) Salte af 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-on-derivater med både muscarinreceptorantagonist- og beta-2-adrenerg-receptoragonistaktiviteter
SG11201505868QA (en) SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
DK3345904T3 (da) Forbindelser med muskarinreceptorantagonist- og beta2-adrenerg receptoragonist-aktivitet
DK3368152T3 (da) Ttfield-behandling med optimering af elektrodepositioner på hovedet baseret på mri-baserede ledeevnemålinger
IL241184A0 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
DK3395814T3 (da) Hæmmere af fibroblastvækstfaktorreceptoren
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
EP2981522A4 (en) PPAR AGONISTS
CO6821950A2 (es) Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
DK2994488T3 (da) Anvendelse af c5ar-antagonister
DK2569308T3 (da) Nye cyclohexylaminderivater med 2-adrenerge agonist- og m3-muskarin antagonistaktiviteter
EP3020707A4 (en) P2X4 RECEPTOR ANTAGONIST
DK2871739T3 (da) Netværksindretning med overvågning af strømforsyning
DK3206692T3 (da) Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister
DK3052101T3 (da) Konjugater af sn-38 med langsom frigivelse
DK3567906T3 (da) Inaktivitetshåndtering af indretninger med forsinkelsestolerant trafik
HRP20150974T1 (xx) Derivati 2-amino-3-(imidazol-2-il)-piridin-4-ona i njihova uporaba kao inhibitora vegf receptora kinaze
EP2578569A4 (en) HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST
DK3052604T3 (da) Anvendelse af afspændingsmidler med alkylglykosider
DK3074139T3 (da) Bruserenhed med brusehovedhus
ME02971B (me) Čvrsti oblici soli alfa-6 -mpeg6-o-hidroksikodona као opioidni agonisti i njihove upotrebe
DK3458040T3 (da) Kombination af rene 5-ht6-receptorantagonister med nmda-receptorantagonist
DK3220942T3 (da) Sammensætninger omfattende lav dosis af desmopressin i kombination med en alpha-adrenerg receptorantagonist
DK2943185T3 (da) Formuleringer med langvarig frigivelse af lorazepam
EP2846800A4 (en) HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS